Skip to main content
DARE
NASDAQ Life Sciences

Dare Bioscience Secures Nearly $1M in Equity Offering Priced at Significant Premium

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$2.974
Mkt Cap
$42.368M
52W Low
$1.27
52W High
$9.19
52W Position info
134% above low
Off High info
68% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

DARE has more than doubled off its 52-week low of $1.27.

Summary

Dare Bioscience raised $975,050 through an equity offering priced at a substantial premium to its current stock price, providing critical capital amidst going concern warnings.


Key Events · Financing and Capital Events · DARE

  • Offering Closings Completed

    Dare Bioscience completed initial closings of its previously announced Regulation A offering on May 1, 4, 5, and 6, 2026.

  • Capital Raised

    The company issued an aggregate of 195,010 Investor Units, generating $975,050 in gross proceeds.

  • Premium Pricing Achieved

    Each Investor Unit was priced at $5.00, which is a significant premium compared to the current common stock price of $2.974.

  • Future Dilution Potential

    The units issued consist of 195,010 shares of Series A Convertible Preferred Stock and Investor Warrants to purchase up to 390,020 shares of common stock, representing potential future dilution upon conversion and exercise.


Analysis · DARE · Life Sciences

Dare Bioscience, facing substantial doubt about its ability to continue as a going concern and Nasdaq delisting risk, has successfully completed initial closings of its Regulation A offering. The company raised $975,050 by issuing 195,010 units, each consisting of preferred stock and warrants. Crucially, these units were priced at $5.00, a significant premium to the current common stock price of $2.974. While dilutive, this capital infusion provides much-needed runway and the premium pricing signals strong investor confidence, which is a critical positive development given the company's financial distress.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DARE was trading at $2.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.4M. The 52-week trading range was $1.27 to $9.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DARE - Latest Insights

DARE
Oct 06, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.844
Real-time Price: $0.6387 info
Change: -$0.2053 (-24%) info
Market Cap: $12.93M info
DARE
Oct 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8428
Real-time Price: $0.6387 info
Change: -$0.2041 (-24%) info
Market Cap: $12.93M info
DARE
Sep 23, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.8074
Real-time Price: $0.6387 info
Change: -$0.1687 (-21%) info
Market Cap: $12.93M info
DARE
Aug 26, 2026, 5:15 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $0.810
Real-time Price: $0.6387 info
Change: -$0.1713 (-21%) info
Market Cap: $12.93M info
DARE
Aug 17, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.900
Real-time Price: $0.6387 info
Change: -$0.2613 (-29%) info
Market Cap: $12.93M info